From Nobel Winning Science to Next Generation Treatment

Event Date: 
Thursday, November 19, 2020
11 a.m.

RNA interference (RNAi) is a scientific breakthrough that, thanks to the determination of both academic and industry researchers, is empowering desperately needed progress against rare diseases. Global health threats like COVID-19 have further demonstrated the significance of this innovative platform.

Join Research!America and partners for a virtual panel discussion focusing on the influence of RNAi technology on medical progress. Participants will explore the impact of RNAi technology in addressing unmet medical needs and demonstrate the symbiotic roles of the public and private sectors.


Elias A. Zerhouni, MD, professor emeritus, Johns Hopkins University, former director, National Institutes of Health, 2002-2008


Isabelle Lousada, president & CEO, Amyloidosis Research Consortium

Phillip A. Sharp, PhD, institute professor, and professor of Biology, MIT; member, Koch Institute for Integrative Cancer Research at MIT; 1993 Nobel Prize in Physiology or Medicine

Akshay Vaishnaw, MD, PhD, president, Research & Development, Alnylam Pharmaceuticals

Brian Zambrowicz, PhD, senior vice president, Functional Genomics and Chief VelociGene® Operations, Regeneron Pharmaceuticals

Program support provided in part by Alnylam Pharmaceuticals

Media Contacts

Terri Schwartzbeck
Director of Communications 

You can change the image of things to come. But you can’t do it sitting on your hands … The science community should reach out to Congress and build bridges.
The Honorable John E. Porter